ARTICLE | Emerging Company Profile
K2 Therapeutics: Spreading bets across range of Asia-sourced assets
Former Legend CEO Ying Huang looks to $250M series A while aiming to replicate an Asia-to-global playbook across a diversified asset portfolio
September 3, 2026 12:02 AM UTC
K2 Therapeutics believes the best way to capture the wave of first- and best-in-class biology emerging from Asia is to spread risk across a portfolio rather than commit heavily to any single asset.
Founded by MPM BioImpact in 2024, the Singapore- and Boston-based holding company emerged from stealth on Aug. 11 with $50 million in seed financing from MPM and former Legend Biotech Corp. (NASDAQ:LEGN) CEO Ying Huang at the helm...